Oral Mucositis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Oral Mucositis – Pipeline Review, H2 2017’, provides an overview of the Oral Mucositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Oral Mucositis

The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects

The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Oral Mucositis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Oral Mucositis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Clevexel Pharma SAS

Colby Pharmaceutical Company

Galera Therapeutics Inc

Humanetics Corp

Innovation Pharmaceuticals Inc

Onxeo SA

Oragenics Inc

Otsuka Holdings Co Ltd

Soligenix Inc

Spectrum Pharmaceuticals Inc

Spherium Biomed SL

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 5

Global Markets Direct Report Coverage 5

Oral Mucositis - Overview 6

Oral Mucositis - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Oral Mucositis - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Oral Mucositis - Companies Involved in Therapeutics Development 21

Clevexel Pharma SAS 21

Colby Pharmaceutical Company 21

Galera Therapeutics Inc 22

Humanetics Corp 22

Innovation Pharmaceuticals Inc 23

Onxeo SA 23

Oragenics Inc 24

Otsuka Holdings Co Ltd 24

Soligenix Inc 25

Spectrum Pharmaceuticals Inc 25

Spherium Biomed SL 26

Oral Mucositis - Drug Profiles 27

AG-013 - Drug Profile 27

BCD-600 - Drug Profile 30

BIO-300 - Drug Profile 31

brilacidin tetrahydrochloride - Drug Profile 34

clonidine hydrochloride ER - Drug Profile 46

CVXL-0095 - Drug Profile 50

dusquetide - Drug Profile 51

EC-18 - Drug Profile 58

GC-4419 - Drug Profile 60

Gene Therapy for Oral Mucositis - Drug Profile 63

Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile 64

GM-0111 - Drug Profile 65

HYLP-006 - Drug Profile 67

KIN-219 - Drug Profile 68

melatonin - Drug Profile 69

phenylbutyrate - Drug Profile 70

pralatrexate - Drug Profile 71

rebamipide - Drug Profile 77

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 79

Oral Mucositis - Dormant Projects 80

Oral Mucositis - Discontinued Products 82

Oral Mucositis - Product Development Milestones 83

Featured News & Press Releases 83

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Tables

List of Tables

Number of Products under Development for Oral Mucositis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Oral Mucositis – Pipeline by Clevexel Pharma SAS, H2 2017

Oral Mucositis – Pipeline by Colby Pharmaceutical Company, H2 2017

Oral Mucositis – Pipeline by Galera Therapeutics Inc, H2 2017

Oral Mucositis – Pipeline by Humanetics Corp, H2 2017

Oral Mucositis – Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Oral Mucositis – Pipeline by Onxeo SA, H2 2017

Oral Mucositis – Pipeline by Oragenics Inc, H2 2017

Oral Mucositis – Pipeline by Otsuka Holdings Co Ltd, H2 2017

Oral Mucositis – Pipeline by Soligenix Inc, H2 2017

Oral Mucositis – Pipeline by Spectrum Pharmaceuticals Inc, H2 2017

Oral Mucositis – Pipeline by Spherium Biomed SL, H2 2017

Oral Mucositis – Dormant Projects, H2 2017

Oral Mucositis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Oral Mucositis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Oral Mucositis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports